Anthem Blue Cross

Precertification Required on Four New Part B Injectables

Anthem Blue Cross is adding the following four new injectable drugs to the 2015 Medicare Advantage list of Part B Injectables / Infusibles requiring precertification. As of March 01, 2015, providers must call for prior authorization of these drugs.

1. Benlysta (belimumab) for treatment of lupus (SLE) (J0490)
   Drugs billed with NOC HCPCS J code (J3490)

2. Iluvien (fluocinolone acetonide injection): for treatment of diabetic macular edema (DME)
   (unlisted, no J code established at this time)

3. Lemtrada (alemtuzumab injection): for treatment of relapsing forms of multiple sclerosis (MS)
   (unlisted, no J code established at this time)

4. Opdivo (nivolumab) for treatment of unresectable or metastatic melanoma (unlisted, no J code established at this time)

Please note for drugs currently billed under the Not Otherwise Classified J code (J3490), the plan’s denial will be for the drug, and not the HCPCS. This applies to all Medicare Advantage Group Sponsored and Individual Medicare Advantage plans.

To contact the plan for prior authorization of these services, see below:
Phone: 866-797-9884 Option 5
Fax: 866-959-1537
Email: muspecialtypharm@anthem.com

Anthem Blue Cross is the trade name of Blue Cross of California: Independent licensee of the Blue Cross Association. ® ANTHEM is a registered trademark of Anthem Insurance Companies, Inc. The Blue Cross names and symbols are registered marks of the Blue Cross Association.